Infective Endocarditis
Conditions
Keywords
Infective Endocarditis, Prognosis, Major Adverse Cardiac and Cerebrovascular event
Brief summary
In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
Detailed description
Infective endocarditis is an inflammation of the inner lining of the heart valves or ventricular walls caused by direct infection of the heart by bacteria, fungi and other microorganisms via the bloodstream route. At present, the clinical diagnosis of IE is mainly based on a combination of typical symptoms, imaging and blood culture, etc. Finding more sensitive means and more accurate indicators for early detection of IE flora distribution characteristics is of great significance for the prevention and targeted treatment of IE. Therefore, in this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
Interventions
Observational; No Interventions were given.
Sponsors
521 Hospital of NORINCO Group
Shaanxi Provincial People's Hospital
Xiangyang Central Hospital
Henan Provincial People's Hospital
First Affiliated Hospital Xi'an Jiaotong University
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with clinically confirmed infective endocarditis
Exclusion criteria
* Patients refuse to sign informed consent form * Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the incidence of MACCE | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | MACCE is major adverse cardio-cerebrovascular events, including myocardial infarction, stroke, vessel revascularization and all-cause death. The MACCE will be assessed from the medical records. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in the incidence of infection recurrence | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | Diagnosis of infective endocarditis by clinical guidelines, which will be assessed from medical records. |
| Change in the incidence of myocardial infarction | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | Myocardial infarction, diagnosed by clinical doctors, will be assessed from medical records. |
| Incidence of adverse thrombus complications | 5 years after the enrollment. | Adverse thrombus complications including systemic embolism, infected aneurysm, splenic abscess, etc. |
| Change in the incidence of vessel revascularization | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | Vessel revascularization, diagnosed by clinical doctors, will be assessed from medical records. |
| Change in the incidence of all-cause death | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | All-cause death, diagnosed by clinical doctors, will be assessed from medical records. |
| Change in the incidence of stroke | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | Stroke, diagnosed by clinical doctors, will be assessed from medical records. |
Countries
China
Contacts
Primary ContactGuoliang Li
Backup ContactYang Yan
Outcome results
None listed